149 related articles for article (PubMed ID: 1338905)
1. Dominant negative mutations in the Wilms tumour (WT1) gene cause Denys-Drash syndrome--proof that a tumour-suppressor gene plays a crucial role in normal genitourinary development.
Hastie ND
Hum Mol Genet; 1992 Aug; 1(5):293-5. PubMed ID: 1338905
[No Abstract] [Full Text] [Related]
2. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
3. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.
Pelletier J; Bruening W; Kashtan CE; Mauer SM; Manivel JC; Striegel JE; Houghton DC; Junien C; Habib R; Fouser L
Cell; 1991 Oct; 67(2):437-47. PubMed ID: 1655284
[TBL] [Abstract][Full Text] [Related]
4. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome.
Baird PN; Santos A; Groves N; Jadresic L; Cowell JK
Hum Mol Genet; 1992 Aug; 1(5):301-5. PubMed ID: 1338906
[TBL] [Abstract][Full Text] [Related]
5. Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene.
Köhler B; Schumacher V; Schulte-Overberg U; Biewald W; Lennert T; l'Allemand D; Royer-Pokora B; Grüters A
Pediatr Res; 1999 Feb; 45(2):187-90. PubMed ID: 10022588
[TBL] [Abstract][Full Text] [Related]
6. Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development.
Bruening W; Bardeesy N; Silverman BL; Cohn RA; Machin GA; Aronson AJ; Housman D; Pelletier J
Nat Genet; 1992 May; 1(2):144-8. PubMed ID: 1302008
[TBL] [Abstract][Full Text] [Related]
7. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion.
Little MH; Williamson KA; Mannens M; Kelsey A; Gosden C; Hastie ND; van Heyningen V
Hum Mol Genet; 1993 Mar; 2(3):259-64. PubMed ID: 8388765
[TBL] [Abstract][Full Text] [Related]
8. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion.
Bardeesy N; Zabel B; Schmitt K; Pelletier J
Genomics; 1994 Jun; 21(3):663-4. PubMed ID: 7959750
[No Abstract] [Full Text] [Related]
9. Genotype/phenotype correlations in Wilms' tumor.
Huff V
Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
[TBL] [Abstract][Full Text] [Related]
10. Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation.
Machin GA
Birth Defects Orig Artic Ser; 1996; 30(1):269-86. PubMed ID: 9125334
[No Abstract] [Full Text] [Related]
11. The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient.
Pritchard-Jones K; Renshaw J; King-Underwood L
Hum Mol Genet; 1994 Sep; 3(9):1633-7. PubMed ID: 7833922
[TBL] [Abstract][Full Text] [Related]
12. A point mutation found in the WT1 gene in a sporadic Wilms' tumor without genitourinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome.
Akasaka Y; Kikuchi H; Nagai T; Hiraoka N; Kato S; Hata J
FEBS Lett; 1993 Feb; 317(1-2):39-43. PubMed ID: 8381368
[TBL] [Abstract][Full Text] [Related]
13. Novel familial WT1 read-through mutation associated with Wilms tumor and slow progressive nephropathy.
Zirn B; Wittmann S; Gessler M
Am J Kidney Dis; 2005 Jun; 45(6):1100-4. PubMed ID: 15957141
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient.
Brown KW; Watson JE; Poirier V; Mott MG; Berry PJ; Maitland NJ
Oncogene; 1992 Apr; 7(4):763-8. PubMed ID: 1314370
[TBL] [Abstract][Full Text] [Related]
15. Do intronic mutations affecting splicing of WT1 exon 9 cause Frasier syndrome?
Kikuchi H; Takata A; Akasaka Y; Fukuzawa R; Yoneyama H; Kurosawa Y; Honda M; Kamiyama Y; Hata J
J Med Genet; 1998 Jan; 35(1):45-8. PubMed ID: 9475094
[TBL] [Abstract][Full Text] [Related]
16. A newly identified exonic mutation of the WT1 gene in a patient with Denys-Drash syndrome.
Tsuda M; Sakiyama T; Owada M; Chiba Y
Acta Paediatr Jpn; 1996 Jun; 38(3):265-6. PubMed ID: 8741319
[TBL] [Abstract][Full Text] [Related]
17. Germline WT1 mutations in Wilms' tumor patients: preliminary results.
Li FP; Breslow NE; Morgan JM; Ghahremani M; Miller GA; Grundy PE; Green DM; Diller LR; Pelletier J
Med Pediatr Oncol; 1996 Nov; 27(5):404-7. PubMed ID: 8827066
[TBL] [Abstract][Full Text] [Related]
18. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.
Rauscher FJ
FASEB J; 1993 Jul; 7(10):896-903. PubMed ID: 8393820
[TBL] [Abstract][Full Text] [Related]
19. RNA processing. Wilms' tumour--the splicing connection?
Lamond AI
Curr Biol; 1995 Aug; 5(8):862-5. PubMed ID: 7583142
[TBL] [Abstract][Full Text] [Related]
20. A novel insertional mutation at the third zinc finger coding region of the WT1 gene in Denys-Drash syndrome.
Ogawa O; Eccles MR; Yun K; Mueller RF; Holdaway MD; Reeve AE
Hum Mol Genet; 1993 Feb; 2(2):203-4. PubMed ID: 8098976
[No Abstract] [Full Text] [Related]
[Next] [New Search]
